Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
CKD: later-stage trial registry
1 of 5 indexed CKD trials are currently recruiting, with more weight in Phase 3-4.
Corpus placement: #3,391 of 28,707 conditions by registered trial count.
5 US clinical trials · 1 currently recruiting · #3,391 of 28,707 conditions by registered trial count
CKD: 5 US clinical trials tracked, 1 recruiting.
CKD is the subject of 5 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 2 are in Phase 3-4 (later-stage) and 0 in Phase 1-2 (earlier-stage). The most active sponsor is Nova Biomedical, running 1 of these trials.
Enrollment posture brief
Registry condition ckd
OPEN 1 | RECR 20% | LATE 2 | EARLY 0 | RANK #3391 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive (20% recruiting · 10 trials)
CKD lists 1 open slots (20% of 5 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for CKD on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
CKD is recruiting below its size-band peers.
1 of 5 indexed trials (20%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates CKD research.
Nova Biomedical accounts for 1 of 5 trials (20%). 5 distinct sponsors appear on at least one study for this condition label.
-
Typical CKD enrolment sits around 150 participants.
Median target enrolment is 150 among the 5 trials that report a genuine target (sentinel values excluded). 1 of those (20%) plan for fewer than 100 participants.
-
CKD research is mostly interventional.
4 interventional and 1 observational studies make up this index (80% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
5 total, page 1 of 1
A Study to Evaluate the Efficacy and Safety of Veverimer for the Treatment of Metabolic Acidosis
Renibus Therapeutics
NCT07355062
ARTEMIS: Ravulizumab to Protect Patients With CKD From CSA-AKI and MAKE
Alexion Pharmaceuticals
NCT05746559
Pregnancy and Contraception Education in Chronic Kidney Disease (PACE-CKD)
University of Michigan
NCT06189807
StatStrip A Glucose/Creatinine Meter System Lay User Study Evaluation
Nova Biomedical
NCT05144971
Reducing Chronic Kidney Disease Burden in an Underserved Population
Baylor Research Institute
NCT03832166
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 3 | 2 |
Top Sponsors
Named interventions
Most-linked intervention names on CKD records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on CKD trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this CKD page
5 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 1 CKD trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Nova Biomedical sponsors the most CKD trials on record, review their full trial history before evaluating a specific study. See Nova Biomedical's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This CKD condition card totals 5 registered trials; most-linked intervention Placebo; top US site state Florida. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.